But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
PD-(L)1 x VEGF bispecifics prove a big draw.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
